Clinical Trial Update: Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study evaluating rapcabtagene autoleucel in participants with diffuse cutaneous systemic sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis

Drugs mentioned

• Rapcabtagene Autoleucel

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Scleroderma, Diffuse | Phase 2 | Status: RECRUITING